


INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional) Army144cont	Application Number 10/696,633
Applicant(s) Hart et al.	
Filing Date Oct. 29, 2003	Group Art Unit 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
SBe		6,340,463 B1	1/22/02	Mitchell et al.	424	263.1	2/18/98

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
SBe	B	WO 00/00617	1/6/00	International application	15/40	7/01		
SBe	C	WO 01/016183	3/8/01	International application	C07K	7/01		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

SBe	D	Volchkov et al., "The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses", FEBS Letters, Vol. 305, No. 3, pages 181-184 (July 1992).
SBe	E	Sanchez et al., "Biochemical Analysis of the Secreted and Viron Glycoproteins of Ebola Virus", J. Virology, Aug. 1998, Vol. 72, pages 6442-6447.

EXAMINER <i>Hay D. Cho</i>	DATE CONSIDERED <i>12/28/2004</i>
-------------------------------	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional)	Application Number
	Army144cont	10/696,633
	Applicant(s) Hart et al.	
	Filing Date	Group Art Unit
	Oct. 29, 2003	1648

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
SBC	F	Wilson et al., "Epitopes Involved in Antibody-Mediated Protection from Ebola Virus", Science, Vol. 387, March 3, 2000, pages 1664-1666.
	G	Ichihashi and Oie, "Neutralizing Epitope on Penetration Protein of Vaccinia Virus", Virology 220, pages 491-494 (1996).
	H	Wolffe et al., "A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies", Virology 211, pages 53-63 (1995).
	I	Roper et al., "Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene", J. Virology, June 1996, Vol. 70, No. 6, pages 3753-3762.
	J	Isaacs et al., "Characterization of a vaccinia virus-encoded 42-kilodalton class I membrane glycoprotein component of the extracellular virus envelope", J. Virology, Dec. 1992, Vol 66, No. 12, pages 7217-7224.
	K	Abstract W33-5, "DNA vaccination against poxviruses using combinations of IMV and EEV immunogens", presented July 2000, American Society for Virology Meeting, pages 113.
	L	Abstract P23-6, "DNA immunization with the vaccinia L1R and/or A33R genes", July 1998, poster at American Society for Virology meeting.
	M	Meyer et al., "Identification of binding sites for neutralizing monoclonal antibodies on the 14-kDa fusion protein of orthodox viruses", Virology 200, Short Communications, pages 778-783 (1994).
	N	Czerny and Mahnel, "Structural and functional analysis of orthopoxvirus epitope with neutralizing monoclonal antibodies", J. General Virology (1990), vol. 71, pages 2341-2352.
	O	Hooper et al., "DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge", Virology 266, pages 329-339 (2000).
	P	Vazquez and Esteban, "Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus", J. Virology, Nov. 1999, Vol. 73, No. 11, pages 9098-9109.
↓	Q	Vazquez et al., "The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal of alpha-helix", J. Virology, Dec. 1998, Vol. 72, No. 12, pages 10126-10137.

EXAMINER	DATE CONSIDERED
Amy B. Cleo	12/28/2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2003

Group Art Unit

1648

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

R

Rodriguez et al., "The vaccinia virus 14-kilodalton fusion proteins forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene", J. Virology, June 1993, Vol. 67, No. 6, pages 3435-3440.

S

Lai et al., "The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals", J. Virology, Oct. 1991, Vol. 65, No. 10, pages 5631-5635.

T

Rodriguez and Esteban, "Mapping and nucleotide sequence of the vaccinia virus gene that encodes a 14-kilodalton fusion protein," J. Virology, Nov. 1987, Vol. 61, No. 11, pages 3550-3554.

U

Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", J. Virology, No. v 1985, vol. 56, no. 2, pages 482-488.

V

NCBI PubMed medline, Abstract for Rodriguez et al., "Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus", J. Virology, No. v 1985, vol. 56, no. 2, pages 482-488.

W

Lin et al., "Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo", J. Virology, Apr. 2000, Vol. 74, No. 7, pages 3353-3365.

X

Gordon et al., "A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope", Virology 181, pages 671-686 (1991).

Y

Ichihashi et al., "Identification of a vaccinia virus penetration protein", Virology 202, pages 834-843 (1994).

Z

Demkowicz et al., "Identification and characterization of vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans", J. Virology, Jan 1992, Vol. 66, No. 1, pages 386-398.

AA

Wilson et al., "Ebola virus: the search for vaccines and treatments", CMLS Cell., Mol. Life Sci., 58 (2001) pages 1-16.

BB

Pushko et al., "Venezuelan Equine Encephalitis virus replicon vector: immunogenicity studies with ebola NP and GP genes in guinea pigs", Vaccines 97, Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratory Press, 1997, pages 253-258.

CC

Geisbert et al., "Evaluation in nonhuman primates of vaccines against Ebola virus", Perspectives, Emerging Infectious Diseases, Vol. 8, No. 5, May 2002, pages 503-507.

EXAMINER

Atacy B Ch

DATE CONSIDERED

12/28/2004

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) Army144cont	Application Number 10/696,633
		Applicant(s) Hart et al.	
		Filing Date Oct. 29, 2002	Group Art Unit 1648

EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
SHE	DD	Pushko et al., "Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus", Vaccine 11 (2000) pages 1-12.
	EE	Wilson et al., "Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins", Virology 286, pages 384-390 (2001).
	FF	Wilson and Hart, "Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein", J. Virology, March 2001, Vol 75, No. 6, pages 2660-2664.
	GG	Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", J. Infectious Diseases, 1999, 179 (Suppl 1), pages S235-S239.
	HH	Jahrting et al., "Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections", J. Infectious Diseases, 1999, 170 (Suppl 1), pages S224-S234.
	II	Volchkov et al., "Release of viral glycoproteins during Ebola virus infection", Virology 245, pages 110-119 (1998).
	JJ	GenBank, Database printout, for Sanchez et al., "Ebola virus nucleoprotein, polymerase complex protein (VP35), matrix protein (VP40), glycoprotein (GP), minor nucleoprotein (VP30), and membrane-associated structural protein (VP24), October 14, 1997 (7 pages).
	KK	Hevey et al., "Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants", Virology 239, pages 206-216 (1997).
	LL	Maruyama et al., "Ebola virus can be effectively neutralized by antibody produced in natural human infection", J. Virology, July 1999, Vol. 73, No. 7, pages 6024-6030.
	MM	Wilson et al., "Ebola virus: the search for vaccines and treatments", CMLS, Cell. Mol. Life Sci. 58 (2001), pages 1826-1841.
	NN	Maruyama et al., "Recombinant human monoclonal antibodies to Ebola virus", J. Infectious Diseases, 1999, 179 (Suppl 1), pages S235-S239)
V	OO	Sanchez et al., "The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing", PNAS, USA, Vol. 93, pages 3602-3607, April 1996.

EXAMINER <i>Stacy B. One</i>	DATE CONSIDERED <i>12/28/2004</i>
---------------------------------	--------------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) Army144cont	Application Number 10/696,633
		Applicant(s) Hart et al.	
		Filing Date Oct. 29, 2003	Group Art Unit 1648

*EXAMINER INITIAL	OTHER DOCUMENTS	(Including Author, Title, Date, Pertinent Pages, Etc.)
JH	PP	Jahrling et al., "Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses", Arch Virol, 1996 (Suppl) 11, pages 135-140.
I	QQ	Parren et al., "Pre- and postexposure prophylaxis of ebola virus infectin in an animal model by passive tranfer of a neutraling human antibody," J. Virology, June 2002, Vol. 76, No. 12, pages 6408-6412.
I	RR	Wilson et al., "Epitopes involved in antibody-mediated protection from ebola virus", Science, Vol. 287, pages 1664-1666, March 3, 2000.
I	SS	Sanchez et al., "Detection and molecular characterization of ebola viruses causing disease in human and nonhuman primates", J. Infectious Diseases, 1999, Vol. 179 (Suppl. 1), pages S164-S169.
I	TT	Sanchez et al., "Biochemical analysis of the secreted and virion glycoproteins of ebola virus", J. Virology, Aug. 1998, Vol. 72, No. 8, pages 6442-6447.
I	UU	Khaw et al., "Technetium-99m labeling of antibodies to cardiac myosin fab and to human fibrinogen", Radiochemistry and Radiopharmaceuticals, J. Nucl. Med., Vol. 23, No. 11, pages 1011-1019, Nov. 1982.
I	VV	Farid et al., "Idiotypes, paratopes and molecular mimicry", pages 1-5, and "An idiotypic approach for a vaccine against hepatitis B surface antigen", pages 285-300, both in Anti-Idiotypes, Receptors, and Molecular Mimicry, Ivy Springer-Verlag, 1988.
I	WW	Kabat et al., "Sequence of proteins of immunological interest, Vol. 1, Fifth ed., pages xiv-xix and 33 pages of sequences (1991).
I	XX	Waldmann, "Manipulation of T-cell responses with monoclonal antibodies", Ann. Rev. Immunol. (1989) 7:407-444.
I	YY	Kennedy et al., "Review: Protein-protein coupling reactions and the applications of protein conjugates", Clinica Chimica Acts 70 (1976) pages 1-31.
I	ZZ	"Continuous cultures of fused cells secreting antibody of predefined specificity", Nature, Vol. 256, pages 495-497 (1975).
I	AAA	Volchkov et al., "Processing of the ebola virus glycoprotein by the proprotein convertase furin", PNAS USA, Vol. 95, pages 5762-5767 (May 1998).

EXAMINER <i>Harg-B. Cho</i>	DATE CONSIDERED <i>12/28/2004</i>
--------------------------------	--------------------------------------

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army144cont

Application Number

10/696,633

Applicant(s)

Hart et al.

Filing Date

Oct. 29, 2003

Group Art Unit

1648

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BBB

Stiles et al., "Production and characterization of monoclonal antibodies against NAJA NAJA ATRA cobrotoxin", Toxicon, Vol. 29, No.10, pages 1195-1204 (1991).

CCC

Feldmann et al., "Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle", Virus Research, 24 (1992) pages 1-19.

DDD

Peters and LeDuc, "An introduction to ebola: the virus nad the disease", J. Infectious Diseases, 1999, Vol. 179 (Suppl 1), pages ix-xvi.

EEE

Kudoyarova-Zubavichene et al., "Preparation and use of hyperimmune serum for prophylaxis and therapy of ebola virus infections", J. Infectious Diseases, 1999, Vol 179 (Suppl 1), pages S218-223.

FFF

Moe et al., "Plaque assay for ebola virus", J. Clinical Microbiology", Apr. 1981, Vol. 13, No. 4, pages 791-793.

~~Waldmann, "Manipulation of T-cell responses wit limonoclonal antibodies", Ann. Rev. Immunol., 1989, Vol. 7, pages 407-444.~~

GGG

duplicate

SBC 2/22/05

HHH

Mikhailov et al., "An evaluation of the possibility of ebola fever specific prophylaxis in baboons", Voprosy Virusologii, No. 2, pages 82-84, 1994.

III

Harlow and Lane, "Antibodies: A Laboratory Manual", Chapter 6, pages 210-213 (Cold Spring Harbor Laboratory, New York) 1988.

JJJ

Schuurs and Van Weemen, "Review" Enzyme-Immunoassay", Clinica Chimica Acta, 81 (1977), pages 1-40.

EXAMINER

Stacy B. Chen

DATE CONSIDERED

12/28/2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.